Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CCXI

ChemoCentryx (CCXI) Stock Price, News & Analysis

ChemoCentryx logo

About ChemoCentryx Stock (NASDAQ:CCXI)

Advanced Chart

Key Stats

Today's Range
$51.99
$51.99
50-Day Range
$51.66
$51.99
52-Week Range
$14.95
$52.00
Volume
113 shs
Average Volume
1.68 million shs
Market Capitalization
$3.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CCXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CCXI Stock News Headlines

Rishi Gupta's Net Worth
Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …tc pixel
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
See More Headlines

CCXI Stock Analysis - Frequently Asked Questions

ChemoCentryx, Inc. (NASDAQ:CCXI) posted its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.13. The biopharmaceutical company had revenue of $17.74 million for the quarter, compared to analysts' expectations of $14.70 million. ChemoCentryx had a negative trailing twelve-month return on equity of 48.52% and a negative net margin of 357.01%.

Based on aggregate information from My MarketBeat watchlists, some other companies that ChemoCentryx investors own include Energy Transfer (ET), Gilead Sciences (GILD), Exelixis (EXEL), Meta Platforms (META), HubSpot (HUBS) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/08/2021
Today
9/16/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CCXI
CIK
1340652
Employees
178
Year Founded
1997

Profitability

EPS (Trailing Twelve Months)
($1.89)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$131.76 million
Net Margins
-357.01%
Pretax Margin
-357.01%
Return on Equity
-48.52%
Return on Assets
-30.59%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
4.54
Quick Ratio
4.47

Sales & Book Value

Annual Sales
$32.22 million
Price / Sales
115.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.09 per share
Price / Book
12.71

Miscellaneous

Outstanding Shares
71,356,000
Free Float
65,433,000
Market Cap
$3.71 billion
Optionable
Optionable
Beta
1.22

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:CCXI) was last updated on 9/16/2025 by MarketBeat.com Staff
From Our Partners